你好,欢迎访问上海交通大学附属第一人民医院公济文库!
所在位置: 首页 - 科室团队导航 - 肿瘤临床医学中心
相关导航
按语种分组
  • 任何
  • 413 中文
  • 372 外文
年代
  • 任何
  • 49 2021
  • 90 2020
  • 60 2019
  • 63 2018
  • 58 2017
  • 45 2016
  • 35 2015
  • 34 2014
  • 18 2013
  • 22 2012
  • 34 2011
  • 18 2010
  • 214 2000-2009
  • 41 1990-1999
按类型分组
  • 任何
  • 366 中文期刊
  • 362 外文期刊
  • 27 中文会议论文
  • 18 中文专利
  • 9 外文专利
  • 更多
按重要期刊分组
  • 任何
  • 315 SCI科学引文索引(美)
  • 261 国内统计源期刊
  • 250 SCIE
  • 213 CSCD中国科学引文库
  • 181 CA化学文摘(美)
  • 更多
按来源刊物分组
  • 任何
  • 23 中国癌症杂志
  • 17 肿瘤
  • 16 中华眼科杂志
  • 13 现代生物医学进展
  • 12 Annals of Onc
  • 更多
科室简介: 成果数量:785

上海交通大学附属第一人民医院肿瘤科是上海市三甲综合医院中最早设立的肿瘤专科,是医院“十二五”期间重点发展的学科之一。2009年,医院整合肿瘤相关学科资源,成立了肿瘤中心,学科带头人黄倩教授,中心主任王理伟教授,肿瘤中心副主任王红霞(兼肿瘤科副主任[主持,南])、刘勇副主任医师,北部执行主任李琦主任医... [详细]

本科室知名学者:
本科室科研趋势: 发文数量 期刊收录
条数据
导出

作者: 包凌云,贾凌云,李朝军,刘禧,刘勇,陆林国,王静,薛恩生,熊华花,谢秀静,张峰,张晓东,张艳 (中国超声医学工程学会浅表器官及外周血管超声专业委员会;国家卫健委脑卒中防治工程专家委员会血管超声专业委员会;中国超声医学工程学会颅脑及颈部血管超声专业委员会;浙江大学医学院附属杭州市第一人民医院;首都医科大学宣武医院;上海交通大学附属第一人民医院;空军军医大学空军特色医学中心;首都医科大学附属北京世纪坛医院;鱼跃集团(意大利百胜医疗);华中科技大学同济医学院附属协和医院;福建医科大学附属协和医院;深圳市第二人民医院;浙江大学医学院附属第一医院;中山大学附属第六医院;厦门大学附属第一医院;郑州大学第一附属医院)

出处: 中国超声医学杂志 2020

关键词: 静脉血流频谱;胡桃夹现象;胡桃夹综合征;股静脉;精索静脉内径;精索静脉曲张;乏氏动作;股浅静脉;专家意见;中国超声医学工程学会;深静脉血栓;左肾静脉;静脉瓣膜;外周静脉血;专家共识

摘要: 超声检查作为血管系统首选的影像学方法,在临床诊疗决策中具有重要的价值。为进一步规范血管超声检查,提高血管超声在临床决策中的地位,保障医疗质量与安全,中国超声医学工程学会浅表器官及外周血管超声专业委员会、国家卫健委脑卒中防治工程专家委员会血管超声专业委员会和中国超声医学工程学会颅脑及颈部血管超声专业委 ...

作者: Yuanpei Li,Zhongling Wang,Xiangdong Xue,Kai Liu (Department of Biochemistry and Molecular Medicine,UC Davis Comprehensive Cancer Center,University of California Davis;Department of Radiology,Shanghai General Hospital,School of Medicine,Shanghai Jiaotong University;Department of Physics,University of California;Georgetown University)

出处: 第十八次中国暨国际生物物理大会 中国广东广州 2020

会议录: 第十八次中国暨国际生物物理大会

摘要: Nanometer-scale distance-dependent physical processes have significantly advanced the fundamental understanding of living systems and facilitated the ...

作者: Ming-Jie Jiang;Dian-Na Gu;Juan-Juan Dai;Qian Huang;Ling Tian (Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;Department of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. Electronic address: TL09168@hotmail.com.)

出处: Trends in cancer 2020 Vol.6 No.5 P419-431

关键词: cancer microenvironment;cell death;chemoradiation;dying cell;tumor repopulation

摘要: Accelerated tumor repopulation following chemoradiation is often observed in the clinic, but the underlying mechanisms remain unclear. In recent years ...

作者: Sun, Yan;Guo, Wei;Bai, Yuxian;Ge, Minghua;Hu, Chaosu;Wu, Shaoxiong;Hao, Junfang;Gao, Ming;Pan, Jianji;Dong, Pin;Wu, Yunong;Liang, Houjie;Wei, Qichun;Zhong, Meizuo;Lu, Taixiang( lutx@mail.sysu.edu.cn) (1 Department of Radiotherapy, Peking University Cancer Hospital & Institute, Beijing, China 2 Ninth People\'s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 3 Department of Medicine, Affiliated Tumor Hospital of Harbin Medical University, Harbin, China 4 Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, China 5 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 6 Department of Radiation Oncology, Sun Yat‐sen University Cancer Center, Guangzhou, China 7 Department of Radiology, Shandong Tumor Hospital & Institute, Jinan, China 8 Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 9 Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China 10 Department of Otolaryngology, Head and Neck Surgery, Shanghai Jiao Tong University Affiliated to Shanghai First People\'s Hospital, Shanghai, China 11 Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China 12 Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China 13 Department of Radiation Oncology, The Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine, Hangzhou, China 14 Department of Oncology, Xiangya Hospital, Central South University, Changsha, China)

出处: Oral Diseases 2020 Vol.26 No.2 P285-294

关键词: China;docetaxel;dose modified;head and neck cancer

摘要: Objective: To evaluate the efficacy and safety of dose‐modified docetaxel plus cisplatin and 5‐fluorouracil (TPF) in Chinese patients with squamous ce ...

作者: Jiang, Ming-jie (AUTHOR);Chen, Yi-yun (AUTHOR);Dai, Juan-juan (AUTHOR);Gu, Dian-na (AUTHOR);Mei, Zhu (AUTHOR);Liu, Fu-rao (AUTHOR);Huang, Qian (AUTHOR);Tian, Ling (AUTHOR)( TL09168@hotmail.com) (1 Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 201620, Shanghai, China 2 Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 201620, Shanghai, China 3 Department of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University, 325000, Zhejiang, China 4 Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 201620, Shanghai, China 5 Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, Shanghai, China)

出处: Molecular Cancer 2020 Vol.19 No.1 P1-15

关键词: Aspirin;DNA damage response;Exosome;microRNA;Pancreatic cancer;Radiotherapy;Tumor repopulating cell;Tumor repopulation

摘要: Background: Tumor repopulation is a major cause of radiotherapy failure. Previous investigations highlighted that dying tumor cells played vital roles ...

作者: Jiashuo Chao, Senlin Zhao, Hongcheng Sun (Affiliations 1 Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine Shanghai 200080, China. 2 Department of Colorectal Surgery, Fudan University Shanghai Cancer Center Shanghai 200032, China.)

出处: American journal of translational research 2020 Vol.12 No.5 P2099-2109

关键词: Hepatocellular carcinoma;dedifferentiation;differentiation therapy;epithelial-mesenchymal transition;liver cancer stem cell;molecular mechanism.

摘要: Hepatocellular carcinoma (HCC) is a common cancer with high morbidity and mortality. Poorer differentiation status indicates worse prognosis of HCC pa ...

作者: Yue Wang, Qianqian Xue, Qiang Zheng, Yan Jin, Xuxia Shen, Mu Yang, Xiaoyan Zhou, Yuan Li (Affiliations 1 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3 Department of Pathology, Shanghai First People\'s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China. yangmu1021@hotmail.com. 4 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. whliyuan@hotmail.com. 5 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. whliyuan@hotmail.com.)

出处: Laboratory investigation; a journal of technical methods and pathology 2020

摘要: SMAD4 is an intracellular signaling mediator of the TGF-β pathway. Its mutation was commonly observed in gastrointestinal cancers, such as pancreatic ...

作者: Midie Xu, Tuanqi Sun, Shishuai Wen, Tingting Zhang, Xin Wang, Yiming Cao, Yu Wang, Xing Sun, Qinghai Ji, Rongliang Shi, Ning Qu (Affiliations 1 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 2 Department of oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3 Institute of Pathology, Fudan University, Shanghai 200032, China. 4 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 5 Department of General Surgery, Shanghai First People\'s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620, China.)

出处: Acta biochimica et biophysica Sinica 2020 Pgmaa092

作者: Yucui Zhao, Yanwei Song, Ruyi Zhao, Minghui Zhao, Qian Huang (Affiliation 1 Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.)

出处: Frontiers in oncology 2020 Vol.10 P607727

关键词: persister cells;prognostic index;radiotherapy;treatment response;tumor repopulation.

摘要: Tumor repopulation during cycles of radiotherapy limits the radio-response in ensuing cycles and causes failure of treatment. It is thus of vital impo ...

作者: Shi, T.;Yin, S.;Zhu, J.;Zhang, P.;Liu, J.;Xiang, L.;Zhu, Y.;Wu, S.;Chen, X.;Wang, X.;Teng, Y.;Zhu, T.;Yu, A.;Zhang, Y.;Feng, Y.;Huang, H.;Bao, W.;Li, Y.;Jiang, W.;Zhang, P.;Li, J.;Ai, Z.;Zhang, W.;Jia, H.;Zhang, Y.;Jiang, R.;Zhang, J.;Gao, W.;Luan, Y.;Zang, R. (a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China; b Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; c Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; d Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China; e Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China; f Department of Gynecology and Obstetrics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; g Department of Gynecology and Obstetrics, Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China; h Department of Biostatistics, Fudan University, Shanghai, China; i Clinical Statistics Center, Shanghai General Hospital, Shanghai, China)

出处: Journal of Gynecologic Oncology 2020 Vol.31 No.3

关键词: Chemotherapy;Clinical Trial;Cytoreductive Surgery;Ovarian Neoplasms;Poly(ADP-ribose) Polymerase Inhibitors

摘要: Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologi ...

肿瘤临床医学中心简介

上海交通大学附属第一人民医院肿瘤科是上海市三甲综合医院中最早设立的肿瘤专科,是医院“十二五”期间重点发展的学科之一。2009年,医院整合肿瘤相关学科资源,成立了肿瘤中心,学科带头人黄倩教授,中心主任王理伟教授,肿瘤中心副主任王红霞(兼肿瘤科副主任[主持,南])、刘勇副主任医师,北部执行主任李琦主任医师。目前,肿瘤中心下设肿瘤内科、肿瘤放疗科、肿瘤介入科、肿瘤基因诊断及生物治疗科。目前肿瘤中心核定床位数185张,科室现有医技人员共50人,其中医生36人,正高级职称7人,副高级职称9人,中级职称18人,具有博士学历11人,硕士学历18人,博士研究生导师3人,硕士研究生导师5人;5人曾在国外进修学习,2人目前正在国外学习。肿瘤中心现为中国抗癌协会临床肿瘤学会(CSCO)执行委员会单位,CSCO胰腺癌专家委员会主任委员单位、CSCO抗肿瘤药物安全管理委员会委员单位、上海市抗癌协会理事单位、上海市医学会肿瘤专科委员会副主任委员单位、上海市肿瘤放射治疗专业委员会委员单位、上海市肿瘤化疗质控中心专家委员单位、上海市肿瘤放疗质控专家委员会单位。
2013年,经全院肿瘤相关专科共同努力,肿瘤中心入选国家临床重点专科建设项目,建设经费500万元。近3年,获得国家级课题(含国家自然科学基金重大研究计划、国家“973”“863”计划、重大国际合作)17项(仅2015年获得国家自然科学基金9项)、市级课题10项,各类科研经费2500余万元。在《Nature Medicine》、《Gastroenterology》等杂志发表高质量SCI论文。在胰腺癌的基础研究与临床诊治方面在上海市乃至全国颇具影响,主持编写了《胰腺癌患者健康教育手册》、中国首部《胰腺癌综合诊治中国专家共识》,为上海市胰腺疾病重点实验室及上海交通大学胰腺癌诊治中心。在人才培养方面,1人入选国家杰出青年基金计划、1人入选“百千万人才工程”国家级人选、1人入选上海市医学领军人才、1人入选上海市优秀学科带头人计划、3人入选上海市“浦江人才计划”。
2013年成立了肿瘤诊治中心以来,肿瘤学科得到迅猛发展。中心集肿瘤预防、诊断、综合治疗和康复为一体,能开展各项专科项目并形成如下医疗特色:
1.肿瘤个体化化疗、靶向治疗、免疫治疗:根据每位患者独特的基因表达情况,制定个体化的化疗方案,联合靶向治疗,极大提高了结直肠癌、肺癌、乳腺癌、胃癌等治疗效果。
2.精准放疗:目前拥有直线加速器3台,其中包括最先进的VARIAN-RapidArc治疗系统,实现了对实体肿瘤的精准放疗。现已开展三维适形放射治疗、调强适形放射治疗、图像引导下的三维适形调强放疗、同步放化疗、PET-CT引导下放疗、立体定向放射治疗等。
3.肿瘤微创治疗:在上海市开展了首例纳米刀治疗局部晚期胰腺癌,还包括高强度超声聚焦治疗系统(HIFU刀)、射频/微波肿瘤消融治疗系统、高频热疗系统、放射性粒子组织间植入治疗系统、氩氦刀低温冷冻肿瘤治疗系统、血管介入等技术,适用于治疗肝癌、肺癌等实体肿瘤。
4.肿瘤分子诊断:包括免疫功能检测、EGFR、K-ras、BRAF等基因突变检测,Her-2基因扩增检测,循环血肿瘤细胞检测等,为肿瘤患者个体化治疗与靶向治疗选择,以及预后判断,提供了更准确的方法。
5.开设肿瘤多学科联合诊治:多学科、多专家共同参与,为患者制定个体化、综合治疗方案,实现对每位肿瘤患者的全称管理,为肿瘤患者提供最科学的诊断治疗技术和最优质的一站式服务。
6.肿瘤生物治疗:全国率先开展生物免疫治疗与现有传统治疗手段(化疗、放疗)综合治疗实体肿瘤(胰腺癌、乳腺癌等),开展单病种肿瘤生物免疫治疗临床研究多项,通过规范病例入组,规范细胞制备与使用,规范疗效评价,并建立相应的疗效评估体系及规范。
7.新药临床研究:在医院药物临床研究机构的监督下,牵头、参与国际多中心临床研究,为结直肠癌、胰腺癌、乳腺癌、胃癌、肺癌等患者提供最新的药物治疗。
8.中心静脉置管及护理: 1999年我科成功置入上海市第一根PICC导管,开创了护士进 行中心静脉置管的新篇章。2006年引入PORT技术,2007年在全国率先开展非超声引导下塞丁格(MST)穿刺技术,2009年引入B超引导下置管技术,新技术的引进提高了PICC置管成功率,解决了临床实际问题。
目前,肿瘤中心的主要研究方向有:胰腺癌的临床及基础研究、胰腺癌炎-癌转化的基础研究、乳腺癌的基础与临床转化研究、三阴性乳腺癌的精准与免疫治疗研究、肿瘤放疗后再增殖研究、肺癌基础研究、转录因子对肝癌发生发展影响的机制研究、基因多态性与化疗敏感性的临床研究、血药浓度检测与化疗敏感性的临床研究等。"